Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Other OTCTotal Valuation
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. carries a market capitalization of 5.76B, placing it among publicly traded companies globally. Its enterprise value stands at 71.31B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.76B |
| Enterprise Value | 71.31B |
Share Statistics
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. currently has 2.67B shares outstanding.
| Shares Outstanding | 2.67B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. trades at a trailing price-to-earnings ratio of 11.41. The price-to-sales ratio is 0.92, and the price-to-book ratio stands at 1.23.
| PE Ratio | 11.41 |
| PS Ratio | 0.92 |
| PB Ratio | 1.23 |
| P/TBV Ratio | 1.24 |
| P/FCF Ratio | 8.44 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. trades at an EV/EBITDA multiple of 25.22 and an EV/FCF ratio of 12.92. The EV/Sales ratio of 1.78 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 25.22 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.78 |
| EV / EBITDA | 25.22 |
| EV / EBIT | 25.22 |
| EV / FCF | 12.92 |
Financial Position
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. maintains a current ratio of 0.95, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 61.34, indicating elevated leverage, while an interest coverage ratio of 2.06 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.95 |
| Quick Ratio | 0.43 |
| Debt / Equity | 61.34 |
| Debt / EBITDA | 13.08 |
| Interest Coverage | 2.06 |
Financial Efficiency
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. posts a return on equity of 11.24 and a return on invested capital of 2.42.
| Return on Equity (ROE) | 11.24 |
| Return on Assets (ROA) | 2.77 |
| Return on Invested Capital (ROIC) | 2.42 |
| Return on Capital Employed (ROCE) | 4.61 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.95 |
Taxes
Over the trailing twelve months, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has paid 893.64M in income taxes, reflecting an effective tax rate of 18.03.
| Income Tax | 893.64M |
| Effective Tax Rate | 18.03 |
Stock Price Statistics
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s stock has gained approximately 10.96939% over the past 52 weeks. The 50-day moving average sits at 2.55, while the 200-day moving average is 2.84.
| Beta (5Y) | N/A |
| 52-Week Price Change | 10.96939% |
| 50-Day Moving Average | 2.55 |
| 200-Day Moving Average | 2.84 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. generated 40.12B in revenue and converted that into 3.25B in net income, yielding earnings per share of 1.54. EBITDA reached 2.83B, while operating income came in at 2.83B.
| Revenue | 40.12B |
| Gross Profit | 19.09B |
| Operating Income | 2.83B |
| Pretax Income | 4.96B |
| Net Income | 3.25B |
| EBITDA | 2.83B |
| EBIT | 2.83B |
| Earnings Per Share (EPS) | 1.54 |
Balance Sheet
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. holds 15.64B in cash and equivalents against 36.99B in total debt, resulting in a net debt position of 16.50B. Total book value stands at 30.08B, with working capital of -1.68B providing operational flexibility.
| Cash & Cash Equivalents | 15.64B |
| Total Debt | 36.99B |
| Net Debt | 16.50B |
| Equity (Book Value) | 30.08B |
| Book Value Per Share | 11.41 |
| Working Capital | -1.68B |
Cash Flow
After subtracting -4.39B in capital expenditures, free cash flow totaled -4.39B - equivalent to -1.66 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -4.39B |
| Free Cash Flow | -4.39B |
| FCF Per Share | -1.66 |
Margins
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. operates with a gross margin of 47.59, reflecting its pricing power and cost economics. The operating margin of 7.05 and net profit margin of 8.09 provide insight into operational efficiency.
| Gross Margin | 47.59 |
| Operating Margin | 7.05 |
| Pretax Margin | 12.35 |
| Profit Margin | 8.09 |
| EBITDA Margin | 7.05 |
Dividends & Yields
The company's payout ratio of 40.84 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.76 |
| Dividend Yield | N/A |
| Payout Ratio | 40.84 |
| Shareholder Yield | 9.59 |
| FCF Yield | 11.85 |
Scores
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. posts an Altman Z-Score of 1.35, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.35 |